 BOULDER, Colo., Feb. 06, 2020 GLOBE NEWSWIRE -- miRagen Therapeutics, Inc. MGEN, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it intends to offer for sale shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering. All of the common stock and warrants to purchase common stock are being offered by miRagen. This offering is being made pursuant to an effective shelf registration statement of miRagen filed with the Securities and Exchange Commission the SEC. 